AU2020903781A0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
AU2020903781A0
AU2020903781A0 AU2020903781A AU2020903781A AU2020903781A0 AU 2020903781 A0 AU2020903781 A0 AU 2020903781A0 AU 2020903781 A AU2020903781 A AU 2020903781A AU 2020903781 A AU2020903781 A AU 2020903781A AU 2020903781 A0 AU2020903781 A0 AU 2020903781A0
Authority
AU
Australia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020903781A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avecho Biotechnology Ltd
Original Assignee
Avecho Biotechnology Ltd
Filing date
Publication date
Application filed by Avecho Biotechnology Ltd filed Critical Avecho Biotechnology Ltd
Publication of AU2020903781A0 publication Critical patent/AU2020903781A0/en
Priority to PCT/AU2021/051212 priority Critical patent/WO2022082257A1/en
Priority to US18/249,647 priority patent/US20230381208A1/en
Priority to AU2021366254A priority patent/AU2021366254A1/en
Priority to CA3195938A priority patent/CA3195938A1/en
Priority to IL302169A priority patent/IL302169A/en
Priority to EP21881370.7A priority patent/EP4228613A1/en
Pending legal-status Critical Current

Links

AU2020903781A 2020-10-19 2020-10-19 Pharmaceutical formulations Pending AU2020903781A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/AU2021/051212 WO2022082257A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
US18/249,647 US20230381208A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
AU2021366254A AU2021366254A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
CA3195938A CA3195938A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
IL302169A IL302169A (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
EP21881370.7A EP4228613A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates

Publications (1)

Publication Number Publication Date
AU2020903781A0 true AU2020903781A0 (en) 2020-11-12

Family

ID=

Similar Documents

Publication Publication Date Title
EP4045480A4 (en) Pharmaceutical formulations
EP3946316A4 (en) Cannabidiol pharmaceutical compositions
EP4028059A4 (en) Stable medicinal cannabidiol compositions
EP4015001A4 (en) Oral pharmaceutical composition
EP4048276A4 (en) Solid pharmaceutical formulations comprising ticagrelor
GB202010230D0 (en) Pharmaceutical formulation
EP3946296A4 (en) Extended release pharmaceutical formulation
EP4058025A4 (en) Pharmaceutical compositions comprising ticagrelor
IL297081A (en) Pharmaceutical formulation
EP3914234A4 (en) Pharmaceutical compositions
EP4034115A4 (en) Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
EP3746080A4 (en) Pharmaceutical formulations
EP3984549A4 (en) Medicinal composition
AU2020903781A0 (en) Pharmaceutical formulations
AU2020903780A0 (en) Pharmaceutical formulations
EP3949952A4 (en) Medicinal composition
TWI800878B (en) Drug set
ZA202212663B (en) Pharmaceutical formulations
IL308250A (en) Pharmaceutical formulations
GB202112820D0 (en) Pharmaceutical formulations
AU2020903873A0 (en) Lymph-Targeting Formulations
AU2020901866A0 (en) Immugenic formulations
GB202005282D0 (en) Pharmaceutical Formulations
GB202003108D0 (en) Pharmaceutical formulations
EP4129276A4 (en) Pharmaceutical composition